Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team
Meeting Host
GASCO & Clinical Care Options, LLCDescription
The Georgia Society of Clinical Oncology (GASCO) cordially invites you to attend a CME/CPE/CE-certified live webinar titled, "Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team." This activity will improve the knowledge, confidence, and competence of learners in applying current data on the use of CDK4/6 inhibitors as part of their care of patients with early-stage breast cancer.
For full accreditation information and to register, visit http://www.clinicaloptions.com/CDK46EBClocal
Faculty
Jane Lowe Meisel, MD
Associate Professor of Hematology and Medical Oncology
Associate Vice Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, Georgia
When
Tuesday, June 11, 2024
6:30 - 7:30 PM ET
Where
Virtual Meeting
Agenda
- Integrating Adjuvant CDK4/6 Therapy for Appropriate Patients With HR-Positive/HER2-Negative EBC in Your Practice
- Strategies for Promoting Adherence and Persistence to Oral Therapy in Your Practice
- Considerations for the Multidisciplinary Team
Target Audience
This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.
Learning Objectives
Upon completion of this activity, learners should be able to:
- Identify patients who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Plan evidence-based personalized treatment strategies for HR-positive/HER2-negative early breast cancer, fostering collaborative discussions and workflows among the oncology multidisciplinary team
- Develop strategies that promote optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer
- Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer
Accreditation Statements
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-028-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.
Disclosures will be made known to learners before the activity.
Provided by Clinical Care Options, LLC.
Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.
© 2024 Clinical Care Options, LLC All rights reserved. 12001 Sunrise Valley Drive, Suite 300, Reston, VA 20191
